إعلان
إعلان

JANX

JANX logo

Janux Therapeutics, Inc. Common Stock

13.44
USD
برعاية
-0.31
-2.24%
٠٦ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

13.45

+0.01
+0.05%

تقارير أرباح JANX

النسبة الإيجابية المفاجئة

JANX تفوق 12 من 18 آخر التقديرات.

67%

التقرير التالي

بيانات التقرير القادم
٢٥ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$170.00K
/
-$0.65
التغير الضمني من Q3 25 (Revenue/ EPS)
-98.30%
/
+66.67%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
+80.56%

Janux Therapeutics, Inc. Common Stock earnings per share and revenue

On ٠٦ نوفمبر ٢٠٢٥, JANX reported earnings of -0.39 USD per share (EPS) for Q3 25, beating the estimate of -0.62 USD, resulting in a 38.07% surprise. Revenue reached 10.00 مليون, compared to an expected 2.99 مليون, with a 234.77% difference. The market reacted with a -7.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 المحللين forecast an EPS of -0.65 USD, with revenue projected to reach 170.00 ألف USD, implying an زيادة of 66.67% EPS, and نقصان of -98.30% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
For Q3 2025, Janux Therapeutics, Inc. Common Stock reported EPS of -$0.39, beating estimates by 38.07%, and revenue of $10.00M, 234.77% above expectations.
The stock price moved down -7.61%, changed from $28.66 before the earnings release to $26.48 the day after.
The next earning report is scheduled for ٢٥ فبراير ٢٠٢٦.
Based on 19 المحللين, Janux Therapeutics, Inc. Common Stock is expected to report EPS of -$0.65 and revenue of $170.00K for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان